Table 1.
Patient information
| HCs < 50 | HCs 50+ | Moderate | Severe | Critical | Follow-up | |
|---|---|---|---|---|---|---|
| Number | 24 | 15 | 5 | 43 | 7 | 5 |
| Mean age (min-max) | 33.7 (22−47) | 54.5 (50−64) | 56.6 (39−78) | 67.5 (28−86) | 64.7 (59−73) | 72 (59−80) |
| Female/total | 7/24 | 11/15 | 1/5 | 17/43 | 1/7 | 1/5 |
| Mean male age/female age | N/D | N/D | 61/39 | 66/69 | 64.8/64 | 72/72 |
| Mean BMI (min-max) | N/D | N/D | 25 (15.5−34.7) | 24.4 (18.3−38) | 29.506 (22−35.9) | 21.99 |
| BMI measured/total | 0/24 | 0/15 | 5/5 | 36/43 | 5/7 | 4/5 |
| Mean male BMI/female BMI | N/D | N/D | 27.41/15.5 | 24.1/24.9 | 31.3/22 | 21.99/ND |
| Diabetes mellitus type 2/total | N/D | N/D | 0/5 | 15/43 | 4/7 | 2/5 |
| COPD/total | N/D | N/D | 0/5 | 3/42 | 1/7 | 1/5 |
| Hypertension/total | N/D | N/D | 1/5 | 18/43 | 2/7 | 2/5 |
| Asthma/total | N/D | N/D | 0/5 | 1/43 | 0/7 | 0/5 |
| Hashimoto disease/total | N/D | N/D | 0/5 | 1/43 | 0/7 | 0/5 |
| Emphysema/total | N/D | N/D | 0/5 | 1/43 | 0/7 | 0/5 |
| Rheumatoid arthritis (no treatment)/total | N/D | N/D | 0/5 | 1/43 | 0/7 | 0/5 |
| Chronic kidney disease (CKD)/total | N/D | N/D | 0/5 | 4/43 | 0/7 | 0/5 |
| Systemic lupus erythematosus (SLE) | N/D | N/D | 0/5 | 0/43 | 0/7 | 0/5 |
| Mean days after symptom onset (min-max) | N/A | N/A | 7.6 (6−9) | 10.5 (6−18) | 14 (6−25) | 62.4 (56−72) |
| Mean days after symptom onset (male/female) | N/A | N/A | 8/6 | 11.5/9.2 | 14/6 | 62.5/64 |
| Mean days after intubation/intubated at the time of sampling | N/A | N/A | N/A (0/5) | 2.02 (42/43) | 3.83 (6/7) | 50.75 (2/5) |
| Mean days after starting steroids (min-max) | N/A | N/A | 1.6 (1−2) | 4.53 (1−13) | 7.14 (1−19) | 55.5 (52−62) |
| Steroid treated/total | N/A | N/A | 5/5 | 43/43 | 7/7 | 5/5 |
| Tocilizumab treated/total | N/A | N/A | 0/5 | 2/43 | 2/7 | 0/5 |